Translocation t(8;14)(q24;q11) with concurrentPTENalterations and deletions ofSTIL/TAL1andCDKN2A/Bin a pediatric case of acute T-lymphoblastic leukemia: A genetic profile associated with adverse prognosis

Skalska‐Sadowska, Jolanta; Dawidowska, Małgorzata; Szarzyńska‐Zawadzka, Bronisława; Jarmuż-Szymczak, Małgorzata; Czerwińska-Rybak, Joanna; Machowska, Ludomiła; Derwich, Katarzyna

doi:10.1002/pbc.26266

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PI3K/Akt/mTOR network is one of the most abnormally expressed signaling pathway in cancer, and recurring mutations have been characterized, including somatic mutations ( PIK3CA , Akt , and PTEN ), amplifications ( PIK3CA , PIK3CB , and Akt ), and deletions (PTEN) . New PI3K/Akt/mTOR–targeted inhibitors with better selectivity and specificity have been developed .…”

Section: Targeted Therapymentioning

confidence: 99%

New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances

Simioni

Bergamini

Ferioli

et al. 2019

Hematological Oncology

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) represents a heterogeneous group of hematologic malignancies, and it is normally characterized by an aberrant proliferation of immature lymphoid cells. Moreover, dysregulation of multiple signaling pathways that normally regulate cellular transcription, growth, translation, and proliferation is frequently encountered in this malignancy. ALL is the most frequent tumor in childhood, and adult ALL patients still correlate with poor survival. This review focuses on modern therapies in ALL that move beyond standard chemotherapy, with a particular emphasis on immunotherapeutic approaches as new treatment strategies. Bi‐specific T‐cell Engagers (BiTE) antibodies, the chimeric antigen receptor (CAR)‐T cells, or CRISPR‐Cas9 (clustered regularly interspaced short palindromic repeats [CRISPR]–associated nuclease 9) represent other new innovative approaches for this disease. Target and tailored therapy could make the difference in previously untreatable cases, i.e., precision and personalized medicine. Clinical trials will help to select the most efficient novel therapies in ALL management and to integrate them with existing treatments to achieve durable cures.

show abstract

Section: Targeted Therapymentioning

confidence: 99%

New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances

Simioni

Bergamini

Ferioli

et al. 2019

Hematological Oncology

View full text Add to dashboard Cite

show abstract

Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation

Zhang,

Wang,

Zhang

et al. 2023

Leukemia & Lymphoma

View full text Add to dashboard Cite

Identification of differential gene expression profile from peripheral blood cells of military pilots with hypertension by RNA sequencing analysis

et al. 2018

View full text Add to dashboard Cite

BackgroundElevated blood pressure is an important risk factor for cardiovascular disease and is also an important factor in global mortality. Military pilots are at high risk of cardiovascular disease because they undergo persistent noise, high mental tension, high altitude hypoxia, high acceleration and high calorie diet. Hypertension is the leading cause of cardiovascular disease in military pilots. In this study, we want to identify key genes from peripheral blood cells of military pilots with hypertension. Identification of these genes may help diagnose and control hypertension and extend flight career for military pilots.MethodsWe use RNA sequencing technology, bioinformatics analysis and Western blotting to identify key genes from peripheral blood cells of military pilots with hypertension.ResultsOur study detected 121 up-regulated genes and 623 down-regulated genes in the peripheral blood mononuclear cells (PBMCs) from hypertensive military pilots. We have also identified 8 important genes (NME4, PNPLA7, GGT5, PTGS2, IGF1R, NT5C2, ENTPD1 and PTEN), a number of gene ontology categories and biological pathways that may be associated with military pilot hypertension.ConclusionsOur study may provide effective means for the prevention, diagnosis and treatment of hypertension for military pilot and extend their flight career.Electronic supplementary materialThe online version of this article (10.1186/s12920-018-0378-2) contains supplementary material, which is available to authorized users.

show abstract

Translocation t(8;14)(q24;q11) with concurrentPTENalterations and deletions ofSTIL/TAL1andCDKN2A/Bin a pediatric case of acute T-lymphoblastic leukemia: A genetic profile associated with adverse prognosis

Cited by 3 publications

References 16 publications

New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances

New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances

Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation

Identification of differential gene expression profile from peripheral blood cells of military pilots with hypertension by RNA sequencing analysis

Contact Info

Product

Resources

About